BACKGROUND
• Breast cancer is the most frequent type of cancer among women, with the highest incidence occurring in North America (91.6 per 100,000) and Western Europe (91.1 per 100,000).
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In these regions, approximately 80% of cases are among women aged 50 years or older. 2 • Endocrine therapy is recommended for most postmenopausal women with metastatic estrogen-receptor-positive and human epidermal growth factor receptor 2-negative (ER+/HER2−) breast cancer.
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However, only 30% of these patients who are initially treated with endocrine therapy have objective tumor regression and another 20% have prolonged stable disease. 4 • Current data on endocrine therapy outcomes among these patients is limited; therefore, recent real-world data on treatment patterns, health care utilization, and clinical outcomes for patients diagnosed with ER+/HER2-metastatic breast cancer are needed.
OBJECTIVES
• To describe patients with ER+/HER2 metastatic breast cancer, including disease characteristics.
• To characterize patterns of treatment received in the metastatic setting, including type of therapy administered, duration of treatment, and reason for stopping treatment.
• To evaluate the effectiveness of current treatments for metastatic breast cancer.
STUDY MEASURES
• Characteristics of women receiving treatment for ER+, HER2-ABC or mBC (e.g., baseline patient demographics [e.g., age, race] and clinical characteristics [e.g., comorbidities, tumor stage and histology])
• Treatment patterns associated with ER+, HER2-ABC or mBC (e.g., agents used, dose, duration of therapy, sequence, reasons for choice of therapy, modification of treatment schedule, switch to subsequent therapies and discontinuation)
• Clinical outcomes (e.g., response rates, Progression Free Survival [PFS] and overall survival) associated with current treatments for women with ER+, HER2-ABC or mBC
• The impact of ER+, HER2-ABC or mBC on work productivity
• Patient reported disease-specific symptoms and quality of life with ER+, HER2-ABC or mBC
• Disease-specific health care resources used by women with ER+, HER2-ABC or mBC
METHODS
• Study design: Retrospective cohort study
• Data source: Medical record abstraction of information from patients treated for metastatic ER+/HER2-breast cancer -Countries included: United Kingdom (UK), Canada (CA), and Belgium and the Netherlands (BENE).
-Data abstraction was conducted in 2015 by 107 physicians across all countries.
• Physician selection criteria -Oncologists and gynecologists who were in practice for 2 to 30 years after the completion of formal training or board certification.
-Treated at least 10 female patients with postmenopausal ER+/HER2-metastatic breast cancer in the past 12 months.
• Patient selection criteria -Females with histologically or cytologically confirmed metastatic ER+/ HER2-breast cancer. Patients either presented with de novo stage IV disease or had a diagnosis of earlier-stage breast cancer that later progressed to metastatic disease.
-Postmenopausal (natural or induced) at the time of metastatic diagnosis.
-Received at least two lines of systemic treatment for metastatic disease; discontinued second line treatment between January 1, 2008, and August 31, 2014.
-Received care from the abstracting physician from the time of metastatic diagnosis to his or her last documented encounter in the medical record.
-No evidence of other concurrent malignancies (except adequately treated non-melanoma skin cancer or other noninvasive neoplasms).
-Did not participate in a breast cancer-related clinical trial or interventional study for any treatment in the metastatic setting.
• Study endpoints -Time to progression (TTP) on first-line treatment was assessed from initiation of first-line treatment to the first observed progression date prior to initiating second-line therapy -Time to progression (TTP) on second-line treatment was assessed from initiation of second-line treatment to the first observed progression date prior to initiating third-line therapy -For patients who did not initiate third-line therapy, progression date was the first observed progression date after discontinuation of second-line therapy.
-Progression-free survival (PFS) on second-line treatment was assessed from initiation of second-line treatment to the first observed progression date occurring before initiating third-line treatment or the first observed progression date or death among those who did not receive third-line treatment.
-Overall survival (OS) was defined as time from metastatic diagnosis to death.
• Data collection -Medical records of eligible patients were selected by participating physicians through a quasi-random sampling approach. Data from the medical records were abstracted and entered into a secure web-based case report form.
-All collected data were anonymized and existed in the medical record at the time of abstraction.
• Ethics and data privacy review -This study type did not require ethics committee reviews in Belgium, Netherlands, or the UK. In the UK, the study type is considered a "Service Evaluation" by National Research Ethical Service.
-This study received an expedited approval by a central IRB committee in CA.
• Analyses -Data were combined and analyzed across all countries as well as separately for the UK, CA, and BENE. Patients and disease characteristics were similar across countries, allowing for pooled analyses.
-Summary statistics were computed to describe patient demographics, clinical characteristics, and treatment patterns.
-Analyses were stratified by line of treatment and type of treatment received (i.e., endocrine therapy, chemotherapy, concomitant chemotherapy and endocrine therapy, or chemotherapy followed by endocrine therapy), where applicable.
-Performance status was measured on the Eastern Cooperative Oncology Group (ECOG) scale or converted from an equivalent Karnofsky score.
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-Progression dates following initiation of each treatment line were defined as the date of first recorded disease progression or death (following second-line only) during the observation period. If a patient progressed between two treatment lines and the date of progression was not recorded, the end of the earlier treatment line was considered the date of progression.
-Patients who did not have an event during the observation period (i.e., did not die and did not progress) were censored at the start of third-line treatment or the date of the last medical record (among those who did not receive third-line treatment).
-OS was estimated using the Kaplan-Meier method. Patients who were alive at the time of data collection were censored at the date of last medical encounter in patient's medical record.
RESULTS

Physician Characteristics
• Participating physicians included medical/clinical oncologists (94.4%), oncologist hematologists (4.7%), and gynecologists (0.9%) practicing in the UK (38.3%), CA (34.6%), or BENE (27.1%).
• Physicians had been in practice an average of 12.4 years and treated an average of 70.4 patients with postmenopausal ER+/HER2-metastatic breast cancer in the last 12 months.
Patient Demographics and Clinical Characteristics
• Data from the medical records of 438 patients (UK 47.7%, CA 29.0%, BENE 23.3%) were collected. Most patients had naturally occurring menopause (92.0%). The mean age at metastatic diagnosis was 61.6 years (standard deviation [SD]: 9.7) ( Table 1 ).
• The majority of the patients were white/Caucasian (85.2%), had no supplemental private insurance (69.0%), and a mean Charlson Comorbidity Index (CCI) score of 1.0 (SD: 1.1) (CCI calculation excluded cancer).
• Nearly two-thirds of patients were initially diagnosed at metastatic stage.
• The most common sites of metastases were bone (66.4%), lung/pleura (47.0%), liver (37.9%), and lymph nodes (34.9%).
• Visceral disease was present in 69.9% of patients.
-Among those who received endocrine therapy only for first-line treatment, 56.7% had visceral disease compared to 87.8% of those who received chemotherapy only, 85.7% of those received chemotherapy and endocrine therapy concomitantly, and 85.4% of those who received chemotherapy followed by endocrine therapy as first-line treatment.
• Upon diagnosis of metastatic disease, 17.1% of patients had a performance status of 0 and 63.0% had a score of 1. 
FIGURE 2: TOP 3 SECOND-LINE REGIMENS
LIMITATIONS
• All patients were required to have received at least two lines of therapy in the metastatic setting for inclusion in the study. Therefore, TTP and OS estimates should not be generalized to all patients treated in the metastatic setting.
• This study utilized a convenience sample as records were obtained from physicians who were willing to participate in the study. Consequently, these findings may differ from the entire population of patients with metastatic ER+/ HER2-breast cancer.
• The abstracted data were limited to the information recorded and available in patients' medical records held by participating physicians.
• Selection bias may have been introduced by exclusion of patients who participated in clinical trials related to treatment of metastatic breast cancer. As high risk patients are typically not included in clinical, the current study may include a higher proportion of non-high risk patients.
• As physicians practicing in real-world treatment facilities do not usually follow a rigid, uniform protocol for assessment of outcomes (e.g., assessing disease progression at specific time intervals as is typically implemented in a clinical trial), TTP and OS estimates should not be directly compared to clinical trial results.
CONCLUSIONS
• Visceral disease was more common in the patients who received chemotherapy than in those who received endocrine therapy
• Disease progression was reported as the key reason for first-and second-line treatment discontinuation (approx. 70%).
• Median TTP was less than 12 months for each treatment line and each type of regimen received.
• Outcomes with current treatments for metastatic breast cancer are not optimal. Novel treatments or regimens with evidence of incremental clinical benefit over current standard of care could address a significant unmet need and contribute to improved outcomes.
